Biotech and pharma outsourcing market seen reaching $101.56 billion by 2030

The biotechnology and pharmaceutical services outsourcing market is projected to grow from $77.21 billion in 2026 to $101.56 billion by 2030, driven by rising clinical research, biologics development and demand for specialized external expertise. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Biotechnology and pharmaceutical services outsourcing is becoming a core support system for drug development, clinical trials and regulatory compliance. - The market’s growth reflects more complex pipelines, tighter regulations and broader use of external expertise by life sciences companies. - Faster outsourcing can help companies cut costs, speed development timelines and bring products to market sooner.

What happened: - The Business Research Company said the global biotechnology and pharmaceutical services outsourcing market was worth $71.87 billion in 2025. - The market is projected to reach $77.21 billion in 2026, which implies 7.4% growth in that period. - The market is forecast to reach $101.56 billion by 2030, at a 7.1% CAGR through the end of the decade. - The report is titled Biotechnology and Pharmaceutical Services Outsourcing Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - A free sample report is available. - The full market report is also available.

The details: - The market’s historical growth has been driven by more complex drug development pipelines. - Global regulatory requirements are adding to demand for outsourced support. - Broader clinical trial activity is increasing the need for external services. - The rise of biotech startups is supporting demand because many smaller firms lack in-house capabilities. - Companies are using outsourcing to access specialized expertise and infrastructure for drug development, clinical trials and compliance work. - Clinical research is a major growth driver because chronic disease prevalence is pushing demand for new therapies. - In November 2023, the Association of the British Pharmaceutical Industry reported a 15% increase in annual recruitment to industry-sponsored clinical trials in the UK, rising from 36,722 participants in 2021/22 to 42,088 in 2022/23. - The market analysis says North America held the largest share in 2025. - The Asia-Pacific region is projected to be the fastest-growing market during the forecast period. - South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa are also included in the regional outlook.

Between the lines: - Demand is shifting toward more specialized outsourcing, not just basic contract services. - The report points to wider use of artificial intelligence in drug discovery as a future growth driver. - Emerging markets are expected to gain from growth in pharmaceutical manufacturing. - The emphasis on lifecycle management and data-driven R&D suggests outsourcing is moving deeper into core strategy, not only back-office support.

What’s next: - The report expects demand to rise as biologics and cell therapy programs expand. - More companies are likely to seek flexible outsourcing partnerships to manage cost and speed pressures. - Regulatory and compliance support should remain a key service area as global oversight tightens. - The Business Research Company says its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel forecasting dashboards, market hotspots infographics, and updated trend analysis. - More information is available through the company’s social channels, including LinkedIn, Facebook and X.